Cite
Braun J, Baraliakos X, Hermann KG, et al. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD Open. 2017;3(1):e000430doi: 10.1136/rmdopen-2017-000430.
Braun, J., Baraliakos, X., Hermann, K. G., Landewé, R., Machado, P. M., Maksymowych, W. P., Davies, O., Hoepken, B., Nurminen, T., Stach, C., & van der Heijde, D. (2017). Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD open, 3(1), e000430. https://doi.org/10.1136/rmdopen-2017-000430
Braun, Jürgen, et al. "Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis." RMD open vol. 3,1 (2017): e000430. doi: https://doi.org/10.1136/rmdopen-2017-000430
Braun J, Baraliakos X, Hermann KG, Landewé R, Machado PM, Maksymowych WP, Davies O, Hoepken B, Nurminen T, Stach C, van der Heijde D. Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD Open. 2017 Apr 24;3(1):e000430. doi: 10.1136/rmdopen-2017-000430. eCollection 2017. PMID: 28848654; PMCID: PMC5566980.
Copy
Download .nbib